Areteia

Pioneering a New Era In Asthma Control

Our Advanced Candidate: Dexpramipexole

Who We Are

About Us
Eosinophilic Asthma

A New Approach

How Did We Get Here?

Phase 3 Development Program

News Releases

Publications

Presentations

Contact
Home Pioneering a New Era
In Asthma Control
Our Advanced Candidate: Dexpramipexole Who We Are
About Us Eosinophilic Asthma
Our Science A New Approach How Did We Get Here Phase 3 Development Program
News News Releases Publications Presentations
Contact

News

  • News Releases
  • Publications
  • Presentations

2022

11.09.22

Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer

Read More

10.05.22

Areteia Therapeutics announces the appointments of Dr. Eric Bradford as Chief Medical Officer, and Robin Walker as Chief Legal Officer and Corporate Secretary

Read More

09.22.22

Areteia Therapeutics named as one of the Most Promising Biotech Startups of 2022

Read More

09.07.22

Ian Read named Chairman of the Board of Areteia Therapeutics

Read More

07.12.22

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding

Read More

02.28.22

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)

Read More

2021

09.07.21

Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

Read More

05.17.21

Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Read More

01.14.21

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Read More

01.04.21

Dexpramipexole Targets Eosinophilic Inflammation

Read More

2020

09.16.20

Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma

Read More

08.17.20

Knopp Biosciences to Present at Oppenheimer’s Private Life Sciences Company Call Series Aug. 18

Read More

2019

07.09.19

Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society

Read More

04.24.19

Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome

Read More

01.16.19

Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases

Read More

2018

05.22.18

NIAID Now: Repurposed Drug Shows Promise for Treating Rare Eosinophilic Diseases

Read More

2017

09.06.17

Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes

Read More

Areteia
Home
|
About Us
|
Eosinophilic Asthma
|
Our Science
|
News
|
Contact
Terms of Service
Accessibility Policy
Privacy
Recruitment Fraud Alert

© 2023 Areteia Therapeutics